ITMI913510A0 - Composizioni farmaceutiche contenenti progesterone ad elevata biodisponibilita' - Google Patents

Composizioni farmaceutiche contenenti progesterone ad elevata biodisponibilita'

Info

Publication number
ITMI913510A0
ITMI913510A0 IT91MI3510A ITMI913510A ITMI913510A0 IT MI913510 A0 ITMI913510 A0 IT MI913510A0 IT 91MI3510 A IT91MI3510 A IT 91MI3510A IT MI913510 A ITMI913510 A IT MI913510A IT MI913510 A0 ITMI913510 A0 IT MI913510A0
Authority
IT
Italy
Prior art keywords
progesterone
pharmaceutical compositions
compositions containing
containing high
high bioavailability
Prior art date
Application number
IT91MI3510A
Other languages
English (en)
Inventor
Sergio Rosini
Fabio Carli
Original Assignee
Istituto Gentili
Vectorpharma Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Gentili, Vectorpharma Int filed Critical Istituto Gentili
Priority to ITMI913510A priority Critical patent/IT1252867B/it
Publication of ITMI913510A0 publication Critical patent/ITMI913510A0/it
Priority to AU32578/93A priority patent/AU3257893A/en
Priority to PCT/EP1992/002982 priority patent/WO1993012797A1/en
Publication of ITMI913510A1 publication Critical patent/ITMI913510A1/it
Application granted granted Critical
Publication of IT1252867B publication Critical patent/IT1252867B/it

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
ITMI913510A 1991-12-31 1991-12-31 Composizioni farmaceutiche contenenti progesterone ad elevata biodisponibilita' IT1252867B (it)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ITMI913510A IT1252867B (it) 1991-12-31 1991-12-31 Composizioni farmaceutiche contenenti progesterone ad elevata biodisponibilita'
AU32578/93A AU3257893A (en) 1991-12-31 1992-12-23 Pharmaceutical compositions containing natural progesterone having a high biological availability
PCT/EP1992/002982 WO1993012797A1 (en) 1991-12-31 1992-12-23 Pharmaceutical compositions containing natural progesterone having a high biological availability

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI913510A IT1252867B (it) 1991-12-31 1991-12-31 Composizioni farmaceutiche contenenti progesterone ad elevata biodisponibilita'

Publications (3)

Publication Number Publication Date
ITMI913510A0 true ITMI913510A0 (it) 1991-12-31
ITMI913510A1 ITMI913510A1 (it) 1993-07-01
IT1252867B IT1252867B (it) 1995-06-28

Family

ID=11361454

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI913510A IT1252867B (it) 1991-12-31 1991-12-31 Composizioni farmaceutiche contenenti progesterone ad elevata biodisponibilita'

Country Status (3)

Country Link
AU (1) AU3257893A (it)
IT (1) IT1252867B (it)
WO (1) WO1993012797A1 (it)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19652196A1 (de) * 1996-12-16 1998-06-18 Jenapharm Gmbh Homogene steroidhaltige Präformulierungen zur Herstellung niedrigdosierter fester und halbfester pharmazeutischer Zubereitungen
IT1296464B1 (it) * 1997-11-19 1999-06-25 Vectorpharma Int Composizioni farmaceutiche in forma di polveri di polimeri reticolati caricati con farmaci e relativo processo di preparazione mediante
US20110312928A1 (en) * 2010-06-18 2011-12-22 Lipocine Inc. Progesterone Containing Oral Dosage Forms and Related Methods
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US20170035781A1 (en) 2015-06-22 2017-02-09 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1230566B (it) * 1988-10-17 1991-10-28 Vectorpharma Int Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione
IT1241417B (it) * 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione

Also Published As

Publication number Publication date
WO1993012797A1 (en) 1993-07-08
AU3257893A (en) 1993-07-28
IT1252867B (it) 1995-06-28
ITMI913510A1 (it) 1993-07-01

Similar Documents

Publication Publication Date Title
DK0585252T3 (da) Farmaceutiske formuleringer
PT589843E (pt) Composicoes farmaceuticas contendo ciclosporinas
EE03108B1 (et) Farmatseutiline kompositsioon
FI981777A0 (fi) Farmaseuttinen ainekoostumus
DE4291156T1 (de) Verbesserte pharmazeutische Zusammensetzungen
ITMI921123A0 (it) Formulazioni farmaceutiche orali contenenti antocianosidi
MX9200622A (es) Composicion farmaceutica
ITTO920303A0 (it) "composizione farmaceutica antiinfiammatoria"
MX9200146A (es) Composiciones farmaceuticas deglutibles
IT1290797B1 (it) Composizioni farmaceutiche stabilizzate
ITMI913510A0 (it) Composizioni farmaceutiche contenenti progesterone ad elevata biodisponibilita'
GB9111314D0 (en) Pharmaceutical compositions
GB9023023D0 (en) Pharmaceutical compositions
DK0511991T3 (da) Farmaceutisk formulering
FI934387A0 (fi) 3-substituerade 2-oxi-indol-1-karboxiamid omfattande farmaceutiska kompositioner
GB9026080D0 (en) Pharmaceutical compositions
NZ238848A (en) Sulphur-substituted mevinic acid compounds and pharmaceutical compositions
GB9003185D0 (en) Pharmaceutical compositions
GB9015435D0 (en) Pharmaceutical compositions
GB9015418D0 (en) Pharmaceutical compositions
ITMI912766A1 (it) Composizione farmaceutica contenente n-acetil-cisteina
SE9101348D0 (sv) Pharmaceutical composition
SE9103213D0 (sv) Farmaceutisk komposition
ITMI922580A0 (it) Composizione farmaceutica
SE9202820D0 (sv) Farmaceutisk komposition

Legal Events

Date Code Title Description
0001 Granted